Log in
Enquire now

List of Palvella Therapeutics, Inc. patents

List of Palvella Therapeutics, Inc. patents
List of Aqwest LLC patents
List of Asthmatx patents
List of Basilea Pharmaceutica patents
List of SBIR/STTR awards granted to Statacorp
List of companies in Forestay Capital's investment portfolio
Patents where
Current Assignee
Name
is
Palvella Therapeutics, Inc.Palvella Therapeutics, Inc.
Name
Description
Patent Applicant
Current Assignee
Inventor
Patent Jurisdiction
Patent Number
Date of Patent
‌
US Patent 11617742 Methods of treating keratin hyperproliferation disorders using mTOR inhibitors

Patent 11617742 was granted and assigned to Palvella Therapeutics, Inc. on April, 2023 by the United States Patent and Trademark Office.

Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
11617742
April 4, 2023
‌
US Patent 11000513 Anhydrous compositions of mTOR inhibitors and methods of use

Patent 11000513 was granted and assigned to Palvella Therapeutics, Inc. on May, 2021 by the United States Patent and Trademark Office.

Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
11000513
May 11, 2021
‌
US Patent 10172789 Compositions for transdermal delivery of mTOR inhibitors

Patent 10172789 was granted and assigned to Palvella Therapeutics, Inc. on January, 2019 by the United States Patent and Trademark Office.

Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
10172789
January 8, 2019
‌
US Patent 10722499 Anyhydrous compositions of mTOR inhibitors and methods of use

Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
10722499
July 28, 2020
‌
US Patent 9855252 Methods of treating keratin hyperproliferation disorders using mTOR inhibitors

Patent 9855252 was granted and assigned to Palvella Therapeutics, Inc. on January, 2018 by the United States Patent and Trademark Office.

Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
9855252
January 2, 2018
‌
US Patent 11135204 Anhydrous compositions of mTOR inhibitors and methods of use

Patent 11135204 was granted and assigned to Palvella Therapeutics, Inc. on October, 2021 by the United States Patent and Trademark Office.

Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
11135204
October 5, 2021
‌
US Patent 11679101 Anhydrous compositions of mTOR inhibitors and methods of use

Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
United States Patent and Trademark Office
United States Patent and Trademark Office
11679101
June 20, 2023
7 results
0 selected
7 results
0 selected
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us